このエントリーをはてなブックマークに追加
ID 16580
Eprint ID
16580
FullText URL
Thumnail 93_519.pdf 940 KB
Title Alternative
Clinical Studies on Chemotherapy for Multiple Myeloma Part II: Response rates, prognostic factors, and side effects in multiple myeloma treated with MIP (Prednisolone and sequential Melphalan and Ifosfamide).
Author
Adachi, Tomiro
Abstract
This report consists of an analysis of 47 patients with multiple myeloma registered between October, 1975, and December, 1980. All of them received Prednisolone together with sequential Melphalan and Ifosfamide (MIP). Clinical studies of the response rates and prognostic factors were conducted and side effects and complications in the treatment of MIP were discussed. The results are summarized as follows: 1. The response rates to MIP therapy as shown by marked diminishment of plasmacytoma and decrease of bone marrow plasmacytosis below 10 per cent were slightly lower than in M, MP, or I therapy. In MIP therapy, the frequency of over 50% reduction of the pretreatment value of M-protein level was 59.6% and the frequency of marked improvement in symptomatic disability was 52.9%. In conclusion, MIP therapy seemed to be better overall in comparison to M, MP, and I. 2. The 50% survival time in 47 patients treated with MIP followed from the initiation of treatment was 19 months. 3. In MIP therapy, the response rate (shown by the reduction of M-protein level) was paradoxically higher in all clinical parameters in the advanced stage group than in the early and intermittent stages. This study made clear the relationship between the survival time and patients characteristics. Of clinical parameters, (1) age, (2) stage IV in the clinical staging of Durie and Salmon, (3) hypercalcemia, (4) extensive bone lytic lesions, and (5) type IV in the patho-morphological stage of Brucher correlated with progressive life span shortage. 5. Patients who responded rapidly (i.e. within 5 weeks) had a longer duration of remission and longer survival than those who responded slowly (6-16 weeks). 6. In stage III, patients who received MIP had a higher response rate and longer survival than those who received M+MP. 7. Side effects and complications reported during MIP treatment were as follows: 1. Bone marrow suppression (Granulocyte≦1000/cmm in 11 cases) 2. Liver damage(GPT≧200 u. in 3 cases) 3. Respiratory infection (in 10 cases) 4. Urinary infection (in 3 cases) 5. Herpes zoster (in 4 cases with IgG-peak) 6. Lung fibrosis (in 2 cases with IgG-peak)
Keywords
多発性骨髄腫
予後因子
多剤併用療法
Published Date
1981-06-30
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume93
Issue
issue5-6
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
519
End Page
536
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
Official Url
https://www.jstage.jst.go.jp/article/joma1947/93/5-6/93_5-6_519/_article/-char/ja/
Related Url
http://www.okayama-u.ac.jp/user/oma/index.html
language
日本語
Copyright Holders
岡山医学会
File Version
publisher
Refereed
True
Eprints Journal Name
joma